Evolus, Inc. Common Stock (EOLS) is a publicly traded Healthcare sector company. As of May 21, 2026, EOLS trades at $6.59 with a market cap of $432.67M and a P/E ratio of -9.80. EOLS moved +2.26% today. Year to date, EOLS is +8.93%; over the trailing twelve months it is -33.84%. Its 52-week range spans $3.86 to $17.82. Analyst consensus is strong buy with an average price target of $14.50. Rallies surfaces EOLS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Revance CEO outlines sales force expansion to boost DAXXIFY growth: Moiz plans to expand Revance’s sales force and provider education to accelerate uptake of DAXXIFY, the first peptide-formulated neuromodulator, alongside SkinPen microneedling and RHA dynamic fillers. He aims to integrate aesthetics, therapeutics and skincare divisions under science-driven innovation to boost revenue growth.
| Metric | Value |
|---|---|
| Price | $6.59 |
| Market Cap | $432.67M |
| P/E Ratio | -9.80 |
| EPS | $-0.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.82 |
| 52-Week Low | $3.86 |
| Volume | 112 |
| Avg Volume | 0 |
| Revenue (TTM) | $301.79M |
| Net Income | $-43.42M |
| Gross Margin | 66.06% |
5 analysts cover EOLS: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.50.